INTRODUCTION
Regulatory T (Treg) cells play a critical role in maintaining immune homeostasis, controlling autoimmune diseases, and inhibiting excessive immune responses against microbes or allergens. 1, 2 Differentiation and function of Treg are regulated by a master regulator, Foxp3. Mutation of Foxp3 in both human and mouse causes lymphoproliferation and massive multiorgan autoimmune inflammation, demonstrating the importance of Foxp3 in Treg cell function. 1, 2 Treg cells can be developed in the thymus as a selection process for cells that express a self-reactive T-cell antigen receptor (TCR) (called thymus-derived Treg, or tTreg), can be differentiated from naïve CD4 T cells in the periphery by antigen stimulation (called peripheral Treg or pTreg), or can be induced in vitro by TGF-b and interleukin (IL)-2 (called induced Treg or iTreg). 1, 2 Recent studies have suggested that Treg cells are composed of heterogeneous populations with different functional properties. 1, 3, 4 T-bet-expressing Treg cells have been shown to accumulate at the Th1 inflammatory sites. 5 These cells express CXCR3, induced by anti-CD40 antibody injection, which prompts the Th1 immune response, 5, 6 and they control the Th1 immune responses induced by Mycobacterium tuberculosis infection. 5 Likewise, IRF4 expressed in Treg cells mediates control of Th2 type immune responses. 7 Treg-specific deletion of IRF4 causes lymphoproliferative diseases associated with a selective increase of IL-4-and IL-5-producing CD4 T cells. 7 Moreover, STAT3 in Treg controls Th17 type immune responses. 8 Treg-specific deletion of STAT3 causes spontaneous fatal intestinal inflammation and excessive IL-17 production. 8 In addition, Bcl-6-expressing Treg cells control follicular helper T cell (Tfh)-mediated immune function. 9, 10 These results suggest that Treg cells use different factors to control a variety of immune responses. Studying the specific function of Treg cells is important for understanding Treg cell-mediated immune regulation and for developing Treg cell-mediated immune therapy.
Although we are beginning to understand several transcription factors in the regulation of different Treg cell functions, we are still far from having a complete understanding of the players and mechanisms involved in heterogeneous Treg cell function. Given the previous findings that Treg cells utilize subset-specific factors to control corresponding subset-specific immune response, we hypothesized that Th1-specific factors control Th1-like Treg functions. Therefore, we searched for transcription factors that are highly expressed in both Treg and Th1 cells using meta-analysis. We discovered interferon regulatory factor 8 (IRF8, also called ICSBP (interferon consensus sequence binding protein)) as a candidate transcription factor, and we examined its role in Th1-like Treg cell function. IRF8-deficient Treg cells expressed aberrantly the Il4 and Il17 genes and reduced the expression of CXCR3. Anti-CD40 treatment, which induces a Th1-polarized immune response, elicited IRF8 expression in Treg cells. IRF8 was induced by Foxp3, which binds to IRF8 promoter. However, IRF8 did not induce T-bet, nor was it induced by T-bet. Our results strongly suggest that Foxp3-induced IRF8 mediates Th1-like Treg cell function independent of T-bet. In vitro CD4 T-cell differentiation Mice were killed and spleens were harvested. Naïve CD4 T cells were isolated from spleens using modified methods from MACS naïve T cell CD4 
MATERIALS AND METHODS

Hepatitis induction
The experiment was done as previously described. 12 Briefly, 10 mg of alpha galactosyl-C18-ceramide (aGal-C18-Cer) (Toronto Research Chemicals Inc., Toronto, Canada) dissolved in 100 ml phosphate-buffered saline (PBS) was given intraperitoneally to each mouse. Twenty-four hours later, the liver was isolated and minced for Percoll gradient centrifuge, and mononuclear cells were harvested. Isolated cells were stained for CD4, CXCR3, and Foxp3 for flow cytometry.
Administration of anti-CD40 antibody
The experiment was done as previously described. 5 Briefly, anti-CD40 antibody (eBioscience) was injected intraperitoneally, 25 mg per mouse on days 0, 2, and 4. Isotype-matching IgG was used as a negative control. On day 6, mice were killed and splenocytes were stained for CD4, Foxp3, and IRF8 for flow cytometry.
Cytokine suppression assay Purified CD45.1 1 naïve CD4 1 T cells were cultured under Th1-polarizing conditions (10 mg mL 21 of plate-bound anti-CD3, 2 mg mL 21 anti-CD28, 1 ng mL 21 IL-2, 3.5 ng mL 21 IL-12 and 5 mg mL 21 anti-IL-4 antibodies) for three days. The activated cells were co-cultured with sorted WT or IRF8-deficient iTreg cells at the ratios of 10:0, 9:1, 7:3, and 5:5 under Th1-polarizing conditions for two days. CD45.1 1 cells were sorted using a FACSAria III (BD Biosciences) and subjected to total RNA isolation. Total RNA isolation and qRT-PCR were performed as described above. Delayed-type hypersensitivity (DTH) assay DTH assay was performed as described previously. 13 Briefly, mice were subcutaneously injected with a mixture of 100 mg grade-V ovalbumin (OVA) (Sigma-Aldrich, St. Louis, USA) in PBS and complete Freund's adjuvant (Sigma) at the base of the tails. Four days later, 600 mg of heat-aggregated grade-II OVA (Sigma) in PBS was intradermally injected into the right-hind footpad of mice and PBS in the left as a control. Forty-eight hours after the challenge, swelling of footpad was measured with a Vernier caliper. Increased thickness was calculated by subtracting the thickness of the unimmunized left foot from that of the immunized right foot.
Statistical analysis
Values are shown as mean 6 standard deviation. Statistical significance of differences between mean values was determined by Student's t-test. Results were considered significant when the p-value was , 0.05.
RESULTS
IRF8 is selectively expressed in Treg and Th1 cells
In our search for transcription factors that are expressed in a Treg-and Th1-specific manner, we examined a previously published database (meta-analysis) on genome-wide gene expression profiles and histone 3 lysine 4 tri-methylation (H3K4-me3) modification from naïve, Th1, Th2, Th17, and Treg cells. 14 We found that gene expression and H3K4-me3 of a transcription factor IRF8 was highly increased in iTreg cells and substantially increased in Th1 cells but not in naïve, Th2, and Th17 cells.
14 Th1-and Treg-specific expression was confirmed by quantitative RT-PCR (qRT-PCR) (Figure 1a) and by western blot analysis (Figure 1b) . We also found that IRF8 was highly expressed in CD4 1
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1 Treg cells but not in CD4 1 CD25 2 cells (Figure 1c ).
Deficiency of IRF8 causes aberrant up-regulation of Il4 and Il17 in Treg
To gain insight into the role of IRF8 in Treg cell differentiation and function, we measured the expression of subset-specific cytokines and transcription factors in in vitro differentiated Treg cells from wild-type or IRF8-deficient mice. Surprisingly, the expression of Il4, Il5, Il13, Il17a, and Il21 genes was aberrantly increased in iTreg cells from IRF8-deficient mice compared to their counterparts of wild-type mice ( Figure 2 ). The expression of Ifng, Foxp3, Tbx21 (encoding T-bet), Gata3, and Rorc (encoding Rorct) genes was no different between cells of wild-type and IRF8-deficient mice ( Figure 2 ). These results suggest that IRF8 represses Th2 and Th17 gene expression in Treg cells, and that this suppressive effect occurs independently of T-bet, GATA3, and Rorct. (Figure 3a) . Among the differentially expressed genes, we found that a chemokine receptor CXCR3 is selectively down-regulated in IRF8-deficient CD4 1 CD25 1 Treg cells compared to their wild-type counterpart (Figure 3a) . Defective expression of CXCR3 in IRF8-deficient CD4 1 CD25 1 Treg cells was confirmed by quantitative RT-PCR (Figure 3b) . Next, we examined whether the reduced CXCR3 expression IRF8-deficient Treg cells was a T-cell intrinsic effect using CD4-specific IRF8-deficient (IRF8 fl/fl 3 CD4-Cre) mice. The frequency of CXCR3
1 Treg cells in the spleen from CD4-specific IRF8 KO mice was reduced compared to that from control mice (Figure 3c) , suggesting that the effect of IRF8 on CXCR3 expression in Treg cells is a T-cell intrinsic.
To get an insight of the molecular mechanism shows IRF8 controls CXCR3 expression in Treg cells, we examined whether IRF8 binds to the Cxcr3 locus by chromatin immunoprecipitation. IRF8 did not bind to the Cxcr3 locus in Treg cells (data not shown). Therefore, the effect of IRF8 on CXCR3 expression in Treg cells seems to be indirect.
CD4-specific IRF8-deficient mice have a defect in the recruitment of CXCR3
1 Treg cells to an inflammation site in an aGal-C18-Cer-induced hepatitis model CXCR3, which was originally shown to be involved in Th1 cell recruitment to sites of type I inflammation, [15] [16] [17] has also been shown to be important in the recruitment of Treg cells to an inflammation site. 5 Next, we examined whether CD4-specific IRF8-deficient mice have a defect in Treg cell recruitment to an inflammation site. For this purpose, we used an aGal-C18-Cer-induced hepatitis model. 12 In this model, aGal-C18-Cerinduced natural killer T cells mediate hepatitis and recruitment of Treg cells to the inflammation site. 12 We induced hepatitis in wild-type and CD4-specific IRF8-deficient mice by injecting aGal-C18-Cer intraperitoneally. After 24 hours, Treg cells in the liver were isolated and analyzed by flow cytometry. Treg cell recruitment was found to be reduced in CD4-specific IRF8-deficient mice (Figure 4 ), suggesting that IRF8 is important in the recruitment of CXCR3
1 Treg cells to the inflammation site.
IRF8 increases in Treg cells during type I inflammation A previous study by Koch et al. has shown that T-bet-deficient
Treg cells show defective expression of CXCR3, and that T-bet controls Treg function during type I inflammation. 5 Reduced expression of CXCR3 in IRF8-deficient Treg cells is reminiscent of T-bet-deficient Treg cells, and suggests that IRF8 may play a role in the regulation of type I inflammation. To test this possibility, we injected wild-type or IRF8-deficient mice with the anti-CD40 antibody, which has been shown to induce a strong Th1 response in mice. 5, 6 Injection of the anti-CD40 antibody induced an increase in IRF8-expressing Treg cells in the spleen (Figure 5a ). We also isolated splenic CD4
1
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2 or CD4 1 CD25 1 cells from mice injected with the anti-CD40 antibody or control rat IgG, and measured expression of Irf8, Tbx21, and Cxcr3 by quantitative RT-PCR. Expression of Irf8 was substantially increased in cells from anti-CD40-injected mice compared to those from control IgGinjected mice (Figure 5b) . Consistent with the previous report, Tbx21 and Cxcr3 were also increased in cells from anti-CD40-injected mice compared to those from control IgG-injected mice 5 ( Figure 5b ). These results suggest that IRF8 is induced in Treg cells during Th1 immune response.
IRF8-expressing Treg cells control cell-mediated immune responses
To examine whether IRF8 plays a role in controlling Th1 response, we first performed a mixed lymphocyte reaction. In vitro-differentiated CD45.1 1 Th1 cells were co-cultured with WT-or IRF8-deficient CD45. 2 1 iTreg cells at the ratios of 10:0, 9:1, 7:3, and 5:5 under Th1-polarizing conditions for two days. CD45.1 1 cells were sorted, and mRNA expression of Ifng was examined by qRT-PCR. IRF8-deficient iTreg cells were less efficient than WT iTreg cells in suppressing Ifng expression in Th1 cells (Figure 6 ), suggesting that IRF8 in Treg cells plays an important role in suppressing Th1 response.
We next performed a DTH assay, a well-known in vivo cellmediated immune response model. Control and CD4-specific IRF8-deficient mice were immunized and challenged on footpad with OVA as an antigen, and then the thickness of swollen footpads was measured after two days. Footpad swelling was exacerbated in CD4-specific IRF8-deficient mice compared to that in control mice (Figure 7a ). We also examined Treg cell populations in the draining lymph nodes from the mice.
Frequencies of Foxp3
1 cells among CD4 T cells and that of CXCR3 1 cells among Treg cells were reduced in the draining lymph nodes of the CD4-specific IRF8-deficient mice compared to those of control mice (Figure 7b and 7c) . This result suggests that IRF8 plays an important role in controlling cellmediated immune responses in vivo and in the recruitment of Treg cells into an inflammation site.
Expression of IRF8 is controlled by Foxp3
Since IRF8 is selectively up-regulated in Treg cells, we examined whether its expression is controlled by Foxp3. We transduced a Foxp3-retroviral vector into naïve CD4 T cells and differentiated them under Th0 conditions in the presence of IL-2. We sorted the transduced cells and measured the expression of Irf8 by quantitative RT-PCR. The expression of Irf8 was found to be 3.5 times higher in Foxp3-transduced cells compared to that in control vector-transduced cells (Figure 8a ). We also transfected control or Foxp3 expression vector into an EL4 mouse thymoma cell line, stimulated with anti-CD3 and anti-CD28, and measured the expression of Irf8 by quantitative RT-PCR. Foxp3 induced Irf8 expression in unstimulated cells and a greater extent in stimulated cells (Figure 8b) , suggesting that the expression of Irf8 is dependent on both Foxp3 and TCR stimulation.
Next, we examined whether IRF8 controls Foxp3 expression. We performed the same retroviral transduction experiment described above with an IRF8-retroviral vector. The ratio of Foxp3 1 cells among GFP positive cells in control-retroviral vector (RV) transduced cells was similar to that in IRF8-RV transduced cells (63% vs. 68%), indicating that overexpression of IRF8 has no effect on Foxp3 expression (Supplementary Figure 1) . This result suggests that IRF8 is under the control of Foxp3 but not vice versa.
IRF8 and T-bet in Treg cells were independently regulated
Because IRF8-deficient Treg cells show a similar phenotype to Tbet-deficient Treg cells, 5 it is plausible that these two transcription factors, IRF8 and T-bet, may influence each other's expression. To test this possibility, we examined whether T-bet induces IRF8, or whether IRF8 induces T-bet in Treg cells, using a retroviral trans- duction experiment. Transduction of T-bet into naïve CD4 T cells and subsequent Treg cell differentiation was found to have no effect on the expression of the Irf8 gene. Likewise, transduction of IRF8 had no effect on the expression of the Tbx21 gene (Supplementary Figure 2) . These results suggest that, even though IRF8 and T-bet exert a similar function in Treg cells, their expression is independently regulated.
DISCUSSION
In the present study, we searched for transcription factors that are selectively expressed in Treg and Th1 cells and discovered IRF8. The IRF8-deficient Treg cells aberrantly expressed the Il4 and Il17 genes, and they exhibited reduced expression of CXCR3, which is a chemokine receptor needed for a Th1 immune response. Anti-CD40 treatment, which induces Th1-polarized immune response, elicited IRF8 expression in Treg cells. IRF8 was induced by Foxp3, which binds to the Irf8 promoter. IRF8 was not found to induce T-bet, nor was it induced by T-bet. These results strongly suggest that Foxp3-induced IRF8 mediates Th1-like Treg cell function independent of T-bet. The primary finding in the present study is that IRF8 mediates Th1-like Treg function. Our study shows that IRF8-deficient Treg cells almost completely lack CXCR3 expression, and that anti-CD40 injection induces IRF8 expression in Treg cells, supporting the important role of IRF8 in the Th1-like Treg cell property. Previous studies suggested that Treg cells are heterogeneous and regulate many specific immune responses. T-bet-expressing Treg cells have been shown to play an important role in regulating the Th1 immune response; 5 IRF4 in Treg mediates regulation of the Th2 immune response, 7 STAT3 in Treg mediates the Th17 immune response, 8 and Bcl6 expressed in Treg cells regulates the Tfh immune response. 9, 10 Our present study adds another transcription factor, IRF8, in this category. T-bet and IRF8 mediate similar functions in Treg cells; however, it seems that their expression is independently regulated. The T-bet-independent role of IRF8 has also been reported in the differentiation of naïve CD8 T cells into effector cytotoxic cells. 18 Whether IRF8 and T-bet play redundant or non-redundant roles in Treg cells awaits further study. Nonetheless, our study suggests that regulation of subset-specific immune response may be more complex than we currently believe, and that more transcription factors and mechanisms may exist to regulate highly diversified and complex immune responses. This notion is supported by a recent report on complex network of transcription factors cooperating with Foxp3 for optimal Treg cell function.
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IRF8 is a member of the IRF family of transcription factors. It controls many aspects of hematopoietic cell differentiation. [20] [21] [22] IRF8 is required for differentiation of macrophages, 11, 23 CD8a 1 DCs, 24, 25 pDCs, 26 B cells, 27 eosinophils, 28 and effector CD8 T cells. 18 It has also been shown to be important in the differentiation of Th1 cells by stimulating macrophages and DCs to produce IL-12. 29, 30 Our study adds another cell type that is regulated by IRF8, i.e., Treg cells. Thus, it seems that IRF8 regulates differentiation or function of many different cell types in the hematopoietic system, and that its functions are cell type-specific.
Recently, Ouyang et al. have shown that IRF8 inhibits Th17 cell differentiation. 31 In our study, IRF8 suppressed IL-17 expression in Treg as well, suggesting that IRF8 plays a similar role in both effector and Treg cells. Ouyang et al. have also shown that the inhibition of Th17 differentiation by IRF8 is not due to reciprocal activation of Treg cells, based on the results that there is no difference in the number and ratio of Treg cells between wild-type and IRF8-deficient mice. There is likewise no difference in the capacity for cure of inflammatory bowel disease by transferring naïve CD4 T cells with wild-type or IRF8-deficient Treg cells into lymphopenic mice. 31 We obtained similar results to these authors. Thus, it seems that IRF8 is not responsible for the general function of Treg cells. Our results suggest that IRF8 specifically controls Th1-like Treg cell function but not the general function of Treg cells.
Migration of Treg cells to tissues or inflammatory sites is essential for surveillance of immune responses and inflammation in tissues. 3, 32 The migration of Treg cells requires interactions of cell adhesion molecules and chemokine-chemokine receptor signaling 3, 32 A variety of different chemokine-chemokine receptors have been shown to play roles in the homing of Treg cells to different sites with various functional properties. 3, 32 CXCR3,which binds to Th1-associated chemokines (CXCL9, CXCL10, and CXCL11), originally had been shown to impact in the Th1 immune response, [15] [16] [17] and subsequently it was found to play a role in homing of Th1-like Treg cells to inflammation sites. 5 The homing of CXCR3 1 Treg cells to tissues has been shown to play a critical role in regulating Th1 immune response induced by infection of M. tuberculosis 5 or Toxoplasma gondii.
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In addition, it exerts a protective effect in graft-versus-host-disease (GVHD) 34 and has an adversal effect in human ovarian carcinomas. 35 Since our study shows that CXCR3 expression is influenced by IRF8 in Treg cells, the controlling of specific IRF8 expression and function or using selected CXCR3 1 Treg cell populations in immune therapy may have great potential for regulating the abovementioned immune functions.
In conclusion, we have shown that IRF8 plays an important role in Th1-like Treg cell function. This study provides an insight that controlling Treg cell function by IRF8 has potential therapeutic value in regulating infection, graft rejection, and tumor progression. The detailed mechanism of IRF8 regulation of Treg cell function awaits further study. 
